Regulatory Filings • Mar 8, 2021
Regulatory Filings
Open in ViewerOpens in native device viewer
BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES
Bergen, Norway, 8 March 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce that Richard Godfrey, CEO of
BerGenBio, will be presenting at the following virtual conferences:
H.C. Wainwright Global Life Sciences Conference
Date: 9-10 March 2021
Presentation available during the conference
Registration for attendees (https://hcwevents.com/globalconference/)
Sachs European Life Sciences CEO Forum
Date: 10-11 March 2021
Live presentation, Thursday 11 March at 13:10 CET
Registration for attendees (https://www.sachsforum.com/14elsf-registration.html)
Carnegie Nordic Virtual Healthcare Seminar
Date: 12 March 2021
Live presentation, Friday 12 March at 11.15 CET
Presentations will be made available on the Company website in the Presentations
section on the day of the respective events:
www.bergenbio.com/investors/presentations/
- END -
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from AXL inhibition: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com
Contacts
Richard Godfrey CEO, BerGenBio ASA
Rune Skeie, CFO, BerGenBio ASA
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs
Consilium Strategic Communications
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
+47 995 13 891
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.